Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
69 hedge funds and large institutions have $84.5M invested in Regulus Therapeutics in 2024 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 11 closing their positions.
245% more call options, than puts
Call options by funds: $38K | Put options by funds: $11K
38% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 16
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
1% less funds holding
Funds holding: 70 → 69 (-1)
4.96% less ownership
Funds ownership: 86.65% → 81.69% (-5%)
5% less capital invested
Capital invested by funds: $89.1M → $84.5M (-$4.54M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.38M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$899K |
| 3 |
BlackRock
New York
|
+$239K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$239K |
| 5 |
JP Morgan Chase
New York
|
+$171K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.26M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$1.49M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$840K |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$661K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$496K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
AQR Capital Management
Greenwich,
Connecticut
| – | -$47.4K | -30,209 | Closed |
|
77
Jane Street
New York
| – | -$46.4K | -29,580 | Closed |
|
78
HSBC Holdings
London,
United Kingdom
| – | -$29.7K | -19,224 | Closed |
|
|
GC
79
Grimes & Company
Westborough,
Massachusetts
| – | -$17.2K | -10,975 | Closed |
|
RGLS Hedge Fund Activity: Q4 2024 in Review
69 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q4 2024, worth a combined $84.5M — down 5.1% from $89.1M a quarter earlier.
Fund positioning in RGLS was balanced in Q4 2024: 11 funds opened new positions, 11 closed out, 22 added to existing stakes and 16 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.38M. The largest seller was T. Rowe Price Associates, cutting an estimated $3.26M.
- 69 institutional investors held Regulus Therapeutics (RGLS) as of Q4 2024, down from 70 in Q3 2024.
- Funds reported $84.5M of Regulus Therapeutics stock for Q4 2024, down 5.1% quarter-over-quarter.
- 11 funds opened new Regulus Therapeutics positions in Q4 2024 and 11 closed out, a net change of 0 holders.
- The largest Regulus Therapeutics buyer in Q4 2024 was Millennium Management, an estimated $1.38M added.
- The largest Regulus Therapeutics seller in Q4 2024 was T. Rowe Price Associates, an estimated $3.26M sold.
Based on aggregated 13F filings for Q4 2024.